2019年11月19日

Hikma企业领导系列的发展筹资Winterlight实验室的AI声乐技术检测中枢神经系统紊乱和追踪疗效的治疗伦敦,11月18日2019——Hikma制药公司(伦敦:HIK)(纳斯达克迪拜:HIK)(场外:HKMPY),(额定Ba1标普、穆迪/ BB +稳定)宣布,其风险投资部门,Hikma企业使得CAD 560万超额认购轮融资Winterlight实验室inc .)与参与第一明星企业,太平洋健康企业,现有投资者的灰色天空venture Partners和其他投资者。多伦多Winterlight实验室inc .)正在开发一个专有的人工智能(AI)技术,将计算语言学,认知神经科学,机器学习,帮助医疗专业人员评估和分析病人的认知健康–包括记忆、思维和推理–从声乐标记在短的演讲片段在平板电脑上。使用一个一分钟的病人样本的自然的演讲,Winterlight小说的方法可以快速、准确地检测各种认知和精神障碍,如痴呆和失语,然后监测治疗的疗效。董事总经理拉娜Ghanem Hikma企业,说,“我们很兴奋进入声乐领域的诊断主要投资Winterlight实验室。我们认识到全球潜在的声音分析诊断、监测和治疗各种疾病和期待着与团队和我们的共同投资者帮助推进技术和扩大疾病领域和地域覆盖,特别是在中东和北非。”Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals. Its priority is to identify and invest in emerging companies in the digital health space globally that have the potential to enhance Hikma's market intelligence and future pipeline. "We are happy to have Hikma Ventures and other investors join Winterlight Labs in our mission to improve the lives of people with dementia and other psychiatric illnesses," commented Liam Kaufman, Co-founder and CEO of Winterlight Labs. "The technology our team is creating will reshape the way healthcare systems track, screen for and assess the effectiveness of treatments for various central nervous system diseases." Winterlight will be using the proceeds of this financing to extend its technology to additional indications, such as schizophrenia and multiple sclerosis, as well as additional languages. "Our ultimate goal is to help patients get better sooner by objectively measuring response to therapy in the real world through speech," continued Kaufman. About Hikma Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com. About Hikma Ventures Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals. Hikma Ventures invests in global start-ups where Hikma's expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinational pharmaceutical company. For more information, please visit www.hikmaventures.com. About Winterlight Labs Inc. Winterlight has developed a tablet-based assessment that is fast, objective, and stress-free. By analysing speech alone, the technology can detect cognitive impairment associated with dementia and mental illness as track the efficacy of related treatments. The Winterlight assessment can be used in life science research, senior care and clinical settings. For more information, please visit https://winterlightlabs.com/.